First interim results from FINE-REAL: a prospective, non-interventional, phase 4 study providing insights into the use and safety of finerenone in a routine clinical setting

医学 内科学 中期分析 肾病科 前瞻性队列研究 肾脏疾病 急诊医学 临床试验 重症监护医学
作者
Susanne B. Nicholas,Ricardo Correa-Rotter,Nihar R. Desai,Lixin Guo,Sankar D. Navaneethan,Kevin M. Pantalone,Christoph Wanner,Stefanie Hamacher,Samuel Fatoba,Andrea Horvat-Broecker,Antonio Garreta-Rufas,Alain Gay,Martin Merz,David C. Wheeler
出处
期刊:Journal of Nephrology [Springer Nature]
标识
DOI:10.1007/s40620-024-02070-y
摘要

Abstract Background Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, improves kidney and cardiovascular outcomes in patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). The FINE-REAL study (NCT05348733) aims to evaluate the characteristics and treatment patterns of participants treated with finerenone in clinical practice. Methods FINE-REAL is a prospective, single-arm, non-interventional study of patients initiated on finerenone as part of their routine care in accordance with country-approved labels. The study, initiated in June 2022, is expected to be completed by January 2028. The cutoff for this pre-specified interim analysis was June 13, 2023. Results Participants were recruited across nephrology, endocrinology, cardiology, and primary care settings. Of 556 participants enrolled in the study by the cut-off date, 504 were included in this analysis (median follow-up duration of 7 months [finerenone treatment initiation to last recorded observation]). At baseline, 76.1% of participants were in the high or very high (KDIGO) CKD risk categories. Angiotensin converting enzyme inhibitors/angiotensin receptor blockers and sodium–glucose cotransporter 2 inhibitors were prescribed to 71.8% and 46.6% of participants, respectively. Based on prescribing information, 87.9% and 12.1% of participants initiated finerenone at doses of 10 and 20 mg, respectively. Finerenone treatment was uninterrupted in 92.3% of participants after 7 months’ median follow-up. Treatment-emergent adverse events occurred in 110 (21.8%) participants. Hyperkalemia occurred in 25 (5.0%) participants, with no cases leading to death, dialysis, or hospitalization. Conclusion At this interim analysis, finerenone was initiated in patients with CKD and T2D across various clinical practices participating in the study. Treatment discontinuation and hyperkalemia occurred infrequently. Graphical abstract
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
小笑驳回了wanci应助
2秒前
gayfall发布了新的文献求助10
4秒前
小龚小龚完成签到 ,获得积分10
4秒前
5秒前
丘比特应助呦呦君必发SCI采纳,获得10
5秒前
6秒前
6秒前
wanci应助吸铁石睡觉采纳,获得10
7秒前
9秒前
10秒前
ygr完成签到,获得积分10
11秒前
12344发布了新的文献求助10
11秒前
汪123发布了新的文献求助10
13秒前
14秒前
小蘑菇应助俭朴山兰采纳,获得10
14秒前
ASHES发布了新的文献求助10
14秒前
科目三应助风中的天菱采纳,获得10
16秒前
16秒前
psycho发布了新的文献求助10
19秒前
华仔应助xzby采纳,获得10
20秒前
20秒前
kento发布了新的文献求助10
20秒前
朽木白哉完成签到 ,获得积分10
21秒前
overThat发布了新的文献求助10
21秒前
21秒前
是哆啦K梦呀完成签到 ,获得积分20
21秒前
23秒前
薰硝壤应助汪123采纳,获得10
23秒前
ZHAZHA完成签到,获得积分10
24秒前
123发布了新的文献求助10
24秒前
十言发布了新的文献求助30
25秒前
26秒前
27秒前
30秒前
kdjm688应助吸铁石睡觉采纳,获得10
31秒前
zfczfc关注了科研通微信公众号
31秒前
有为发布了新的文献求助10
32秒前
32秒前
隐形曼青应助hehe_733采纳,获得10
32秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Pharmacogenomics: Applications to Patient Care, Third Edition 1000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
《粉体与多孔固体材料的吸附原理、方法及应用》(需要中文翻译版,化学工业出版社,陈建,周力,王奋英等译) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3084389
求助须知:如何正确求助?哪些是违规求助? 2737327
关于积分的说明 7544689
捐赠科研通 2386947
什么是DOI,文献DOI怎么找? 1265702
科研通“疑难数据库(出版商)”最低求助积分说明 613158
版权声明 598320